8-K Announcements
6Material company update
May 22, 2026·SEC
Material company update
May 11, 2026·SEC
Material company update
May 4, 2026·SEC
Perspective Therapeutics, Inc.(CATX)Earnings, Financials & Key Ratios
CATX•AMEX
$3.03
Price updated Jun 27, 2026
AboutPerspective Therapeutics, Inc., together with its subsidiaries, develops, manufactures, sells, and markets isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is based in Richland, Washington.Show more
- Revenue$0
- EBITDA-$110M-1154.7%
- Net Income-$103M-30.1%
- EPS (Diluted)-1.40-13.8%
- ROE-41.44%+4.4%
CATX Price & Volume
Perspective Therapeutics, Inc. (CATX) stock price & volume — 10-year historical chart
Loading chart...
Capital Intensive Pivot Strains Liquidity Runway
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Contracting
Profitability:Negative
Financial Position:Vulnerable
Cash Flow:Burning
Primary Risk:Clinical Trial Funding Gap
"Perspective Therapeutics is currently navigating a high-risk transition from legacy medical device operations to a capital-intensive radiopharmaceutical development platform. While the firm is aggressively scaling its Lead-212 infrastructure, the lack of consistent commercial revenue and persistent net losses of $26.2M in 2026Q1 create significant uncertainty regarding long-term solvency. Investors should monitor the company's ability to manage its $94.9M in net PPE and $40.0M in goodwill against a rapidly depleting cash balance that has fallen from $252.0M in 2024Q2 to $54.0M in 2026Q1."
Verdict Logic
the company's rapid cash depletion, which saw reserves drop to $54.0M in 2026Q1, suggests an urgent need for additional financing to sustain its current R&D-heavy operating model.
CATX Growth Metrics
Perspective Therapeutics, Inc. (CATX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-30.48%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-16.53%
Return on Capital
10 Years-41.66%
5 Years-27.7%
3 Years-31.6%
Last Year-40.47%
CATX Recent Earnings
Perspective Therapeutics, Inc. (CATX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 6/12 qtrs (50%)●Beat Revenue 5/12 qtrs (42%)
Q2 2026Latest
May 11, 2026Metric
Actual
Est
EPS
$0.25+13.8%
$0.29
Rev
$76,000-51.7%
$157,381
Q2 2026
Mar 16, 2026Metric
Actual
Est
EPS
$0.51-37.8%
$0.37
Rev
$43,000-81.5%
$232,478
Q4 2025
Nov 10, 2025Metric
Actual
Est
EPS
$0.35-6.1%
$0.33
Rev
$209,000-10.1%
$232,480
Q3 2025
Aug 13, 2025Metric
Actual
Est
EPS
$0.30+0.0%
$0.30
Rev
$234,000+34.0%
$174,600
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 11, 2026 | $0.25vs $0.29+13.8% | $76,000vs $157,381-51.7% |
| Q2 2026 | Mar 16, 2026 | $0.51vs $0.37-37.8% | $43,000vs $232,478-81.5% |
| Q4 2025 | Nov 10, 2025 | $0.35vs $0.33-6.1% | $209,000vs $232,480-10.1% |
| Q3 2025 | Aug 13, 2025 | $0.30vs $0.30+0.0% | $234,000vs $174,600+34.0% |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Perspective Therapeutics, Inc. (CATX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $3.03 | $234.07M | -2.16 | — | — | -41.44% | — | |
| $3.03 | $126.18M | -891.18 | 10.37% | 52.16% | — | — | |
| $6.19 | $2.25B | 19.67 | 43.31% | 7.82% | 7.42% | — | |
| $109.80 | $7.15B | 32.20 | 0.5% | 18.05% | 24.33% | — | |
| $0.45 | $66.61M | -0.86 | -3.98% | -1460.9% | -113.15% | — | |
| $182.08 | $38.71B | -30.60 | — | — | -83.22% | — |
Compare CATX vs Peers
Perspective Therapeutics, Inc. (CATX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
CATX SEC Filings & Documents
Perspective Therapeutics, Inc. (CATX) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when CATX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
CATX Frequently Asked Questions
Perspective Therapeutics, Inc. (CATX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Perspective Therapeutics, Inc.'s revenue?
Perspective Therapeutics, Inc. (CATX) reported $0.6M in revenue for fiscal year 2025. This represents a 93% decrease from $8.3M in 1996.
Is CATX profitable?
Perspective Therapeutics, Inc. (CATX) reported a net loss of $111.1M for fiscal year 2025.
Dividend & Returns
What is CATX's return on equity?
Perspective Therapeutics, Inc. (CATX) has a return on equity (ROE) of -41.4%. Negative ROE indicates the company is unprofitable.
What is Perspective Therapeutics, Inc.'s free cash flow?
Perspective Therapeutics, Inc. (CATX) had negative free cash flow of $107.3M in fiscal year 2025, likely due to heavy capital investments.